Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD Eye on Ocular Health
-
- 과학
Host: Diana V. Do, MD
Guest: Peter K. Kaiser, MD
This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.
Host: Diana V. Do, MD
Guest: Peter K. Kaiser, MD
This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.